In March 2021, Health regulatory authorities in the European Union (EU) and Brazil formed a partnership to promote mutual recognition and regulatory harmonization, improving human and animal health. This partnership provided the framework under which EU and Brazilian health regulatory authorities will develop their regulatory cooperation [1].

The collaborations between ANVISA and DKMA spans key areas like clinical practice inspections, medical devices, artificial intelligence in regulation, and antimicrobial resistance. The next phase will expand on these priorities, ensuring both agencies remain at the forefront of regulatory innovation.

Moving forward, ANVISA and DKMA plan to enhance their technical exchanges through joint workshops, expert visits, and collaborative research. These efforts will focus on advancing the regulation of emerging health technologies, improving the quality and safety of medical devices, and integrating artificial intelligence intoregulatory processes. By deepening their partnership, both agencies seek to strengthen their regulatory frameworks and better address evolving public health challenges.

Such international cooperation is vital for addressing global health issues, aligning regulatory standards, and enhancing response capabilities. This renewed agreement underscores the importance of cross-border collaboration in building a safer and healthier future.

Related articles
Challenges and progress in the registration of biosimilars in Latin America

Strategic plans of ANVISA and COFEPRIS to advance health regulation

Regulatory landscape for biosimilars in Latin America 

Reference
1. GaBI Online - Generics and Biosimilars Initiative. EU and Brazil health authorities enter partnership [www.gabionline.net]. Mol, Belgium: Pro Pharma Communications International; [cited 2025 May 6]. Available from: www.gabionline.net/policies-legislation/EU-and-Brazil-health-authorities-enter-partnership

Permission granted to reproduce for personal and non-commercial use only. All other reproduction, copy or reprinting of all or part of any ‘Content’ found on this website is strictly prohibited without the prior consent of the publisher. Contact the publisher to obtain permission before redistributing.

Copyright – Unless otherwise stated all contents of this website are © 2025 Pro Pharma Communications International. All Rights Reserved.